Johannes Holzmeister

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Synecor LLC (Synecor) is a venture capital firm founded in 2000 by Richard S. Stack, William N. Starling, and Judith L. Swain. The firm is headquartered in Chapel Hill, North Carolina.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Cardiogen Sciences, Inc. is a biotechnology company that develops and offers gene therapy solutions for orphan-inherited arrhythmogenic diseases. The company was founded by Louis G. Lange in 2014 and is headquartered in Palo Alto, CA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

VantagePoint Management, Inc. (VantagePoint) is a venture capital firm founded in 1996 by Alan Edward Salzman, James D. Marver. The firm is headquartered in Santa Barbara, California with additional office in Beijing, China.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

Institute for Systems Biology operates as a nonprofit biomedical research organization. It develops a systems approach to characterize, predict, and manipulate state transitions in biological system. The company was founded by Leroy E. Hood, Ruedi Aebersold and Alan Aderem in 2000 and is headquartered in Seattle, WA.

Seqens SASU engages in pharmaceutical and healthcare industries. The company was founded on April 2, 2003 and is headquartered in Ecully, France.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Part of Japan Lifeline Co., Ltd., Cardiac Rhythm Management is a company that manufactures implantable devices to treat arrhythmias. The company is based in Sylmar, CA.

Part of Community Health Systems, Inc., Jewish Hospital is a hospital. The company is based in Cincinnati, OH. Jewish Hospital was acquired by Mercy Health Partners, Inc. (Pennsylvania), a NPO of Community Health Systems, Inc. from Jewish Foundation of Cincinnati on March 01, 2010 for $180 million.

The Heart Care Group is an outpatient cardiac care practice that prioritizes wellbeing and preventative care. The American company offers a new take on cardiac wellness.

InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.

Asset Management Ventures LLC (AMV) is a venture capital subsidiary of Asset Management Co. founded in 1965 by Franklin Pitcher Johnson. The firm is headquartered in Palo Alto, California.

Maverix Biomics, Inc. provides cloud-based platform to manage, analyze and visualize genomic data. It also builds communities of discovery and place its data in context with the latest public data from the full spectrum of life, including human, plant, animal or microbial organisms. The company was founded by David Mandelkern, Todd Michael Johnson Lowe and Patricia Pak Lee Chan in 2010 and is headquartered in San Mateo, CA.

Revitope Oncology, Inc. develops a programmable antibody circuit pipeline in particular redirecting T cells to tumors. The company was founded by Andrew Allen and Mark Cobbold and is headquartered in Cambridge, MA.

Teon Therapeutics, Inc. operates as a pharmaceutical company. It focuses on cancer immunotherapy. The company was founded by Yao Lina, Fan Peidong, Elfaith Elzein, and Liiu Jiwen in March 2018 and is headquartered in Redwood City, CA.

SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA.

Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.